AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8687088 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable self‐reinforced polyglycolide or polylactide devices
Number of subjects: 69
Study 8687088 — intervention group
Group type: COMPARATOR
Intervention: Non‐operative treatment
Number of subjects: 69
Study 2087015 — intervention group
Group type: COMPARATOR
Intervention: AS‐4370 2.5 mg
Number of subjects: 0
Study 2087015 — intervention group
Group type: EXPERIMENTAL
Intervention: AS‐4370 5 mg
Number of subjects: 0
Study 2087015 — intervention group
Group type: EXPERIMENTAL
Intervention: AS‐4370 10 mg
Number of subjects: 0
Study 2087015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 517369 — intervention group
Group type: EXPERIMENTAL
Intervention: WH question format
Number of subjects: 151
Study 517369 — intervention group
Group type: COMPARATOR
Intervention: Incomplete statement format
Number of subjects: 151
Study 6819596 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (150-300 mg per day)
Number of subjects: 98
Study 6819596 — intervention group
Group type: COMPARATOR
Intervention: Chlorimipramine (150-300 mg per day)
Number of subjects: 98
Study 31585522 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 41
Study 31585522 — intervention group
Group type: COMPARATOR
Intervention: Placebo LLLT
Number of subjects: 41
Study 31585522 — intervention group
Group type: EXPERIMENTAL
Intervention: Active LLLT
Number of subjects: 41
Study 31585522 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about treatment
Number of subjects: 41
Study 30359072 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction over 2 days
Number of subjects: 142
Study 30359072 — intervention group
Group type: COMPARATOR
Intervention: Maintained sleep over 2 days
Number of subjects: 142
Study 30359072 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Number of subjects: 142
Study 29614401 — intervention group
Group type: EXPERIMENTAL
Intervention: DIGIT training program
Number of subjects: 49
Study 29614401 — intervention group
Group type: EXPERIMENTAL
Intervention: PLUS training program
Number of subjects: 49
Study 29614401 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 preschoolers with no mathematical difficulties)
Number of subjects: 49
Study 26982446 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention for medication adherence or symptom severity
Number of subjects: 462
Study 26982446 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention
Number of subjects: 462
Study 24737712 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib
Number of subjects: 803
Study 22796985 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patches
Number of subjects: 15
Study 22796985 — intervention group
Group type: COMPARATOR
Intervention: Placebo transdermal patches
Number of subjects: 15
Study 19703761 — intervention group
Group type: EXPERIMENTAL
Intervention: GLA+prandial insulin lispro (LIS)
Number of subjects: 395
Study 19703761 — intervention group
Group type: COMPARATOR
Intervention: GLA+prandial regular human insulin (RHI)
Number of subjects: 395
Study 19703761 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (LIS and RHI)
Number of subjects: 395
Study 17351283 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 66
Study 17351283 — intervention group
Group type: COMPARATOR
Intervention: Support visits (Control)
Number of subjects: 66
Study 16327946 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Pycnogenol
Number of subjects: 18
Study 16327946 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment (oral and local)
Number of subjects: 18
Study 12017143 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line domestic violence education program
Number of subjects: 65
Study 12017143 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not take the program)
Number of subjects: 65
Study 10589610 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 30
Study 10589610 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 7608367 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement
Number of subjects: 47
Study 7608367 — intervention group
Group type: COMPARATOR
Intervention: Resin fissure sealant
Number of subjects: 47
Study 2239719 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride fish oil (6 g/day)
Number of subjects: 89
Study 2239719 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl ester fish oil (7 g/day)
Number of subjects: 89
Study 2239719 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (12 g/day)
Number of subjects: 89
Study 35925 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0
Study 31842993 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day treatment with 40 mg prednisone daily followed by 2 days of placebo (experimental arm, n = 235)
Number of subjects: 470
Study 31842993 — intervention group
Group type: COMPARATOR
Intervention: 5-day treatment with 40 mg prednisone daily (conventional arm, n = 235)
Number of subjects: 470
Study 28969350 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip abductor strength in surgical limb pre-TKA
Number of subjects: 162
Study 28969350 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip abductor strength in surgical limb 1 month post-TKA
Number of subjects: 162
Study 28969350 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip abductor strength in surgical limb 3 months post-TKA
Number of subjects: 162
Study 28969350 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in hip abductor strength from pre-TKA to 1 month post-TKA
Number of subjects: 162
Study 28969350 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in hip abductor strength from 1 month to 3 months post-TKA
Number of subjects: 162
Study 28969350 — intervention group
Group type: EXPERIMENTAL
Intervention: Contribution of hip abductor strength to performance-based outcomes pre-TKA
Number of subjects: 162
Study 28969350 — intervention group
Group type: EXPERIMENTAL
Intervention: Contribution of hip abductor strength to performance-based outcomes post-TKA
Number of subjects: 162
Study 26414337 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (2 mg daily, titrated from 0.5 mg during first week)
Number of subjects: 160
Study 26414337 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 160
Study 26414337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 22392603 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral iron therapy
Number of subjects: 148
Study 22392603 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly oral iron therapy
Number of subjects: 148
Study 22392603 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly oral iron therapy
Number of subjects: 148
Study 21397895 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure only
Number of subjects: 58
Study 21397895 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure with safety behavior availability
Number of subjects: 58
Study 21397895 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure with safety behavior utilization
Number of subjects: 58
Study 19770129 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 80 mg/m² on day 1 and irinotecan 60 mg/m² on days 1 and 8 followed by accelerated hyperfractionated thoracic radiotherapy (60 Gy/40 fractions in 4 weeks) with daily carboplatin (CBDCA) administration.
Number of subjects: 26
Study 19770129 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) and irinotecan chemotherapy followed by radiotherapy with daily carboplatin.
Number of subjects: 26
Study 17288330 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-activated resin composite with incremental technique
Number of subjects: 40
Study 17288330 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-activated resin composite with bulk technique
Number of subjects: 40
Study 17288330 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical-activated resin composite with incremental technique
Number of subjects: 40
Study 17288330 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical-activated resin composite with bulk technique
Number of subjects: 40
Study 14724304 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg of albendazole per day and 6 mg of dexamethasone per day for 10 days
Number of subjects: 120
Study 14724304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 12572707 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 80
Study 12572707 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 80
Study 12572707 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Doxazosin and HCTZ
Number of subjects: 80
Study 9498726 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole 12 mg daily with alprazolam 1 mg
Number of subjects: 14
Study 7620470 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral family systems therapy (BFST)
Number of subjects: 22
Study 7620470 — intervention group
Group type: COMPARATOR
Intervention: Ego-oriented individual therapy (EOIT)
Number of subjects: 22
Study 2131867 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% with epinephrine 1:200,000
Number of subjects: 15
Study 2131867 — intervention group
Group type: COMPARATOR
Intervention: Plain bupivacaine 0.5%
Number of subjects: 15
Study 31846795 — intervention group
Group type: EXPERIMENTAL
Intervention: Eczema (past/current)
Number of subjects: 12049
Study 31846795 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring Atopic Dermatitis
Number of subjects: 12049
Study 31846795 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics in the first week of life
Number of subjects: 12049
Study 31846795 — intervention group
Group type: EXPERIMENTAL
Intervention: Current rhinitis
Number of subjects: 12049
Study 31846795 — intervention group
Group type: EXPERIMENTAL
Intervention: Eczema severity
Number of subjects: 12049
Study 31846795 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of introduction of egg into the diet
Number of subjects: 12049
Study 31666778 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast self-examination
Number of subjects: 810
Study 31666778 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived severity of breast cancer
Number of subjects: 810
Study 31666778 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 810
Study 31666778 — intervention group
Group type: EXPERIMENTAL
Intervention: Districts
Number of subjects: 810
Study 31666778 — intervention group
Group type: EXPERIMENTAL
Intervention: Place of residence
Number of subjects: 810
Study 31666778 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Belief Model (HBM)
Number of subjects: 810
Study 30040523 — intervention group
Group type: COMPARATOR
Intervention: Placebo with doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (arm A)
Number of subjects: 4994
Study 30040523 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab only during AC and paclitaxel (arm B)
Number of subjects: 4994
Study 30040523 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab during AC and paclitaxel followed by bevacizumab monotherapy for 10 cycles (arm C)
Number of subjects: 4994
Study 27763932 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki
Number of subjects: 45
Study 27763932 — intervention group
Group type: COMPARATOR
Intervention: Sham Reiki
Number of subjects: 45
Study 27763932 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study 24866910 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast consumption for one week
Number of subjects: 37
Study 24866910 — intervention group
Group type: COMPARATOR
Intervention: No breakfast consumption for one week
Number of subjects: 37
Study 21901486 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed breastfeeding (MBF)
Number of subjects: 0
Study 21901486 — intervention group
Group type: COMPARATOR
Intervention: Exclusive breastfeeding
Number of subjects: 0
Study 19923501 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mL of 6% HES 130/0.42 in a balanced electrolyte solution (n = 25)
Number of subjects: 50
Study 19923501 — intervention group
Group type: COMPARATOR
Intervention: 500 mL of 5% human albumin plus 1000 mL 0.9% saline solution (n = 25)
Number of subjects: 50
Study 17574511 — intervention group
Group type: EXPERIMENTAL
Intervention: mini-CPB
Number of subjects: 30
Study 17574511 — intervention group
Group type: COMPARATOR
Intervention: conventional CPB
Number of subjects: 30
Study 15480509 — intervention group
Group type: EXPERIMENTAL
Intervention: [(18)F] fluoromisonidazole (FMISO) PET
Number of subjects: 16
Study 15480509 — intervention group
Group type: COMPARATOR
Intervention: [(18)F]-2-fluoro-2'-deoxyglucose (FDG) PET
Number of subjects: 16
Study 11592538 — intervention group
Group type: EXPERIMENTAL
Intervention: Team midwife care
Number of subjects: 1000
Study 11592538 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1000
Study 9560031 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperimmune bovine colostrum (n=42)
Number of subjects: 135
Study 9560031 — intervention group
Group type: COMPARATOR
Intervention: Ordinary colostrum (n=42)
Number of subjects: 135
Study 9560031 — intervention group
Group type: COMPARATOR
Intervention: Milk (n=41)
Number of subjects: 135
Study 7635023 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study 7635023 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine
Number of subjects: 0
Study 2974791 — intervention group
Group type: EXPERIMENTAL
Intervention: DianeR (cyproterone acetate 2 mg and ethinylestradiol 50 micrograms per pill - D-50)
Number of subjects: 30
Study 2974791 — intervention group
Group type: EXPERIMENTAL
Intervention: Diane 35 (cyproterone acetate 2 mg and ethinylestradiol 35 micrograms per pill - D-35)
Number of subjects: 30
Study 29305893 — intervention group
Group type: EXPERIMENTAL
Intervention: Franseen needle
Number of subjects: 50
Study 29305893 — intervention group
Group type: COMPARATOR
Intervention: Fork-tip needle
Number of subjects: 50
Study 26239663 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-targeted ventilation (VTV)
Number of subjects: 40
Study 26239663 — intervention group
Group type: COMPARATOR
Intervention: Pressure-limited ventilation (PLV)
Number of subjects: 40
Study 24656555 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administration of sc DMPA 104 mg
Number of subjects: 137
Study 24656555 — intervention group
Group type: COMPARATOR
Intervention: Clinician administration of sc DMPA 104 mg
Number of subjects: 137
Study 24429865 — intervention group
Group type: EXPERIMENTAL
Intervention: Candibiotic ear drops
Number of subjects: 0
Study 24429865 — intervention group
Group type: COMPARATOR
Intervention: Otipax ear drops
Number of subjects: 0
Study 24429865 — intervention group
Group type: COMPARATOR
Intervention: Anauran ear drops
Number of subjects: 0
Study 20236172 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150-600 mg/day
Number of subjects: 254
Study 20236172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 17845740 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster A (elevated paranoid and schizotypal features)
Number of subjects: 90
Study 17845740 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster B (elevated narcissistic and histrionic features)
Number of subjects: 90
Study 17845740 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster C (elevated avoidant and obsessive-compulsive features)
Number of subjects: 90
Study 17845740 — intervention group
Group type: EXPERIMENTAL
Intervention: Two dimensions underlying comorbid features: extraversion versus introversion and antagonism versus constraint
Number of subjects: 90
Study 15864235 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin (10/10, 10/20, 10/40, or 10/80 mg)
Number of subjects: 1902
Study 15864235 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin (10/40 and 10/80 mg)
Number of subjects: 1902
Study 15864235 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin (10, 20, 40, or 80 mg)
Number of subjects: 1902
Study 15864235 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin
Number of subjects: 1902
Study 15864235 — intervention group
Group type: COMPARATOR
Intervention: ezetimibe/simvastatin and atorvastatin
Number of subjects: 1902
Study 12818960 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen treatment
Number of subjects: 517
Study 11029973 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 25
Study 11029973 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 25
Study 11029973 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in restrained eaters
Number of subjects: 25
Study 11029973 — intervention group
Group type: COMPARATOR
Intervention: Rest conditions
Number of subjects: 25
Study 8852908 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized human IgG (Sandoglobulin) at a dose of 0.1 g/kg in a 5% solution, delivered in 2 parts on the day of hospital admission.
Number of subjects: 68
Study 8852908 — intervention group
Group type: COMPARATOR
Intervention: Placebo, identical amount as the treatment group, delivered in 2 parts on the day of hospital admission.
Number of subjects: 68
Study 8475011 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including physician involvement and community education effort
Number of subjects: 0
Study 8475011 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (comparison community)
Number of subjects: 0
Study 2880743 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LAS) infusion (66 mg/min for 120 min)
Number of subjects: 10
Study 2880743 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (SRIF) infusion (150 micrograms bolus followed by 100 micrograms/h for 120 min)
Number of subjects: 10
Study 2880743 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine (25 g i.v. in 30 min)
Number of subjects: 10
Study 2880743 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LAS) infusion
Number of subjects: 10
Study 30089729 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise (EE) - 1 hour of bicycling at 70% of VO2peak
Number of subjects: 10
Study 30089729 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE) - 1 hour of high-volume RE
Number of subjects: 10
Study 26790922 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 cm excision margin
Number of subjects: 900
Study 26790922 — intervention group
Group type: COMPARATOR
Intervention: 3 cm excision margin
Number of subjects: 900
Study 26384407 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) ingestion (0.4 g/kg body weight)
Number of subjects: 9
Study 26384407 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) ingestion
Number of subjects: 9
Study 26384407 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride)
Number of subjects: 9
Study 24267044 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fructose corn syrup (HFCS)
Number of subjects: 138
Study 24267044 — intervention group
Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 138
Study 21616485 — intervention group
Group type: EXPERIMENTAL
Intervention: PGS
Number of subjects: 131
Study 21616485 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 131
Study 19090341 — intervention group
Group type: EXPERIMENTAL
Intervention: CLIN/RA gel (clindamycin phosphate 1.2%-tretinoin 0.025%)
Number of subjects: 655
Study 16551762 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational health intervention programme
Number of subjects: 260
Study 16551762 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 260
Study 12701861 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic intravitreal injection of vancomycin 1 mg and ceftazidime 2.25 mg
Number of subjects: 70
Study 12701861 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic intravitreal antibiotics)
Number of subjects: 70
Study 11131100 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 1070
Study 8930551 — intervention group
Group type: EXPERIMENTAL
Intervention: Pesticide use levels (four levels of pesticide use assigned to municipalities)
Number of subjects: 0
Study 8930551 — intervention group
Group type: EXPERIMENTAL
Intervention: Pesticide use levels
Number of subjects: 0
Study 8930551 — intervention group
Group type: COMPARATOR
Intervention: Level 0 pesticide use (control group)
Number of subjects: 0
Study 1329475 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (2.5-10 mg once daily)
Number of subjects: 18
Study 1329475 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10 mg once daily)
Number of subjects: 18
Study 1329475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 4054521 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileal infusion of lipid emulsion (50% corn oil, 3% albumen)
Number of subjects: 6
Study 4054521 — intervention group
Group type: COMPARATOR
Intervention: Control infusion of albumen and saline
Number of subjects: 6
Study 4054521 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileal infusion of corn oil emulsions
Number of subjects: 6
Study 4054521 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of fat emulsion
Number of subjects: 6
Study 4054521 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of isosmotic saline
Number of subjects: 6
Study 31387615 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional strapping reduction
Number of subjects: 56
Study 31387615 — intervention group
Group type: COMPARATOR
Intervention: Towel clamp reduction
Number of subjects: 56
Study 27520015 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT)
Number of subjects: 16
Study 27520015 — intervention group
Group type: EXPERIMENTAL
Intervention: EFT
Number of subjects: 16
Study 27520015 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 16
Study 29873988 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-free anesthesia
Number of subjects: 66
Study 29873988 — intervention group
Group type: COMPARATOR
Intervention: Opioid anesthesia
Number of subjects: 66